Recursion Pharmaceuticals (RXRX) Cost of Revenue (2022 - 2026)

Recursion Pharmaceuticals' Cost of Revenue history runs 5 years deep, the most recent figure standing at $12.5 million for Q1 2026.

• Quarterly Cost of Revenue fell 42.78% year-over-year to $12.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61.6 million (up 10.22% YoY) and the FY2025 annual result came in at $71.0 million, up 56.84% from the prior year.
• Cost of Revenue was $12.5 million for Q1 2026 at Recursion Pharmaceuticals, down from $14.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $21.8 million in Q1 2025 and bottomed at $7.8 million in Q1 2022.
• A 5-year average of $12.9 million and a median of $12.4 million in 2023 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2025 — Cost of Revenue jumped 119.17% — and 2026, when it sank 42.78%.
• Recursion Pharmaceuticals' Cost of Revenue stood at $10.8 million in 2022, then decreased by 8.85% to $9.9 million in 2023, then increased by 29.48% to $12.8 million in 2024, then gained by 11.58% to $14.3 million in 2025, then decreased by 12.5% to $12.5 million in 2026.
• Business Quant data shows RXRX's Cost of Revenue at $12.5 million in Q1 2026, $14.3 million in Q4 2025, and $14.7 million in Q3 2025.